Leveraging miRNAs to concurrently target transcription factors such as SP1 and MYC may provide synergistic therapeutic benefits, paving the way for innovative combination strategies that exploit the vulnerabilities of cervical cancer. The gene discussed is MYC; the disease is cervical cancer.